Search research articles
Contact Us
Filters
Showing results (141-150 of 179) with videos related to
Page
of 18
Sort By:
Clinical Colorectal Cancer
|
November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Jeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Lancet (London, England)
|
December 18, 2007
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F Chu, Maria A Rupnick, Risto Kerkela, et al.
The American Journal of Gastroenterology
|
September 18, 2013
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations
Dmitri Mouradov, Enric Domingo, Peter Gibbs, et al.
Cancer Research
|
December 17, 2013
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling
Kathleen I Pishas, Susan J Neuhaus, Mark T Clayer, et al.
Cold Spring Harbor Molecular Case Studies
|
November 4, 2020
Recurrent <i>SPECC1L-NTRK</i> fusions in pediatric sarcoma and brain tumors
Dong-Anh Khuong-Quang, Lauren M Brown, Marie Wong, et al.
The Journal of Clinical Investigation
|
March 6, 2019
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
Christopher R McEvoy, Huiling Xu, Kortnye Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
Eva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
Cancer Discovery
|
June 9, 2018
<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors
Anuratha Sakthianandeswaren, Marie J Parsons, Dmitri Mouradov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial
Patrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 179) with videos related to
Sort By:
Page
of 18
Clinical Colorectal Cancer
|
November 23, 2018
Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study
Jeremy D Shapiro, Subotheni Thavaneswaran, Craig R Underhill, et al.
Lancet (London, England)
|
December 18, 2007
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F Chu, Maria A Rupnick, Risto Kerkela, et al.
The American Journal of Gastroenterology
|
September 18, 2013
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations
Dmitri Mouradov, Enric Domingo, Peter Gibbs, et al.
Cancer Research
|
December 17, 2013
Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling
Kathleen I Pishas, Susan J Neuhaus, Mark T Clayer, et al.
Cold Spring Harbor Molecular Case Studies
|
November 4, 2020
Recurrent <i>SPECC1L-NTRK</i> fusions in pediatric sarcoma and brain tumors
Dong-Anh Khuong-Quang, Lauren M Brown, Marie Wong, et al.
The Journal of Clinical Investigation
|
March 6, 2019
Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion
Christopher R McEvoy, Huiling Xu, Kortnye Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2016
Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study
Eva Segelov, Subotheni Thavaneswaran, Paul M Waring, et al.
Cancer Discovery
|
June 9, 2018
<i>MACROD2</i> Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors
Anuratha Sakthianandeswaren, Marie J Parsons, Dmitri Mouradov, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial
Patrick Schöffski, Roberta Sanfilippo, Javier Martín-Broto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Page
of 18